The development of proteasome inhibitor (PI) and immunomodulatory drugs (IMiDs) have considerably changed the treatment paradigm of multiple myeloma (MM), while significantly improving survival. Nevertheless, many patients exhibit disease relapse and develop drug resistance. The better understanding of disease biology will likely influence our approach to myeloma treatment, resulting in the advent of newer drug classes, such as monoclonal antibodies and adoptive cellular therapies. There is much hope that MM will soon become a chronic illness with sustained complete response in a significant number of patients.
Key words
Multiple myeloma – novel agents – monoclonal antibodies – target therapies